| INTRODUCTION
Asthma is recognized as a heterogeneous and complex disease, with distinct therapeutic approaches which depend upon its phenotypic classification.
1-3 "Exacerbation-prone" asthma has been identified as a potentially distinct asthma phenotype, linked with high morbidity and mortality in people with asthma. [4] [5] [6] [7] [8] In fact, prevention of asthma exacerbations is one of the major goals of current asthma treatment guidelines. 9 Therefore, identifying patients at the greatest risk of future exacerbations and achieving good asthma control is key to preventing future exacerbations and ultimately reducing health care
costs.
With regard to the clinical predictive factors for future asthma exacerbation, the significance of the so-called "T-helper 2 (Th2)-related inflammatory biomarkers," including blood/sputum eosinophil levels, immunoglobulin E level (IgE), and fractional excretion of nitric oxide (FeNO) concentration, has been investigated in many retrospective studies. 4, 5, 10, 11 Meanwhile, "past exacerbation history" has been identified as the strongest factor with which to predict future asthma exacerbation. 7, 8 Despite the existence of this simple and readily-obtainable clinically information, no studies have considered this factor in relation to the significance of biomarkers. In other words, to identify any novel biomarkers with clinical utility, we should evaluate whether any biomarkers could be independent predictors of the "future asthma exacerbations," over that of exacerbation history alone. Most previous studies have been retrospective or with limited 1-year follow-up. 4, 5, [7] [8] [9] [10] [11] [12] In this study, using the obtained at the subjects' study entry point for the Hokkaido Severe Asthma Cohort Study, we previously reported the clinical characteristics of such subjects, with particular focus upon upper and lower airway inflammation and airflow limitation in relation to smoking status. 13 We recently finished the 3-year follow-up, in which we yearly made repeated measurements of clinical and biological parameters.
The goal of the current study was to characterize the clinical and biomarker features associated with asthma exacerbations in severe asthma. In particular, we aimed to evaluate the clinical utility of several Th2-related biomarkers for the prediction of future asthma exacerbation over that of exacerbation history alone.
| MATERIALS AND METHODS
The details of the materials and methods used in this study were described in our previous report 13 and can be found in the Supporting Information.
| Study protocol and subjects
The Hokkaido Severe Asthma Cohort Study (the Hokkaido-based
is a multicenter observational cohort study, which primarily aims to characterize subjects with severe asthma, including those who smoke. The details of this study protocol have been reported previously. 13 Patients with severe asthma were enrolled at Hokkaido 14 with slight modification. In brief, we also included the criteria as follows. The diagnosis of severe asthma required one or both major criteria and 2 minor criteria. Patients who were well-controlled under the current medications were asked if within 1 year they experienced episodic deterioration of symptoms, urgent care visits, and rescue use of short-acting bronchodilators when the dose of the current medication was reduced. 13 A total of 127 patients with severe asthma were selected for baseline analyses. 13 A flow chart demonstrating the study process from the initial screening of Visit Entry (VE) to Visit 1-year (V1), Visit 2-year (V2), and the end of the 3-year follow-up period (Visit 3-year, V3) is depicted in Figure S1 .
| Assessment of exacerbation
We defined asthma exacerbation based on the need for systemic corticosteroids for more than 3 days and/or hospital admission, which corresponds to "severe exacerbation" based on the European Respiratory Society (ERS)/ATS guideline of severe asthma. 15 Frequent exacerbators were defined as those who had 2 or more exacerbations within 1 year of follow-up, whereas non-exacerbators were defined as those who did not have any annual events.
| Measurement of biomarkers
The concentration of FeNO was measured with the NIOX MINO â (Aerocrine, Stockholm, Sweden) using a single-breath online method, in accordance with the ATS guidelines. 16 We also measured blood eosinophil counts, serum total/specific IgE, and serum periostin level.
Detail methods of measurements of other biomarkers were described in our previous report 13 and can be found in the Supporting Information.
| Questionnaires
Upon study entry and during every hospital visit, the clinical research coordinators (CRCs) directly administered comprehensive questionnaires to all subjects; the information assessed included their asthma symptom score (as assessed by the asthma control test), as well as symptoms of gastroesophageal reflux disease (GERD), depression, and allergic rhinitis (see Supporting Information). The presence of aspirin-exacerbated respiratory disease (AERD) was diagnosed by the chief respiratory physician and confirmed by the CRCs.
| Pulmonary function testing
Spirometry was performed before and after inhalation of 400-lg oxitropium and 400-lg salbutamol. Further details of the pulmonary function tests are described in our previous report. 13 
| Assessment of adherence to medications
As described in our previous study, 13 we excluded subjects who were assessed by a doctor (Dr. NT) and the CRCs to have poor adherence to their medications and inadequate medication inhalation technique upon their initial visit. Table S1 shows the patients' adherence to their medications during the study period. Subjects with low adherence (<70%) were excluded from the final analyses. 
| Analysis 2 (from V1 to V3: 2-year follow-up)
To confirm the results from Analysis 1 (from VE to V3), using the data at initial entry (VE), we conducted similar analyses using the data obtained at V1, over 2-year follow-up (from V1 to V3; Figure 1) . We classified subjects into 3 groups: (i) consistent nonexacerbators in analysis2 (CNE-2), subjects who did not have any exacerbation episodes over 2 years; (ii) consistent frequent exacerbators in analysis 2 (CFE-2), subjects who fulfilled the criteria for frequent exacerbation throughout the 2-year period; and (iii) intermittent exacerbators in analysis 2 (IE-2), subjects who did not fulfil either of the 2 previously described criteria. In the multivariate analyses, we also considered the "exacerbation status during the first year" (Model 2, Figure 1 ). In addition to generalized estimating equations (GEE), models for repeated binary outcomes were applied to calculate odds ratios for the associations of several variables with repeated measures of exacerbation status.
Statistical analyses were performed using the statistical software package SYSTAT for Windows, version 13.1 (SYSTAT, San Jose, CA, USA), EZR, version 1.27 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for the R software (The R Foundation for Statistical Computing, Vienna,
The study protocol of this study. Once a year, all subjects visited Hokkaido University and underwent serial clinical evaluations after confirming that their asthmatic symptoms were unchanged during the past 2 wk. Analysis 1: Analyses over 3-y follow-up using the data obtained at VE. Analysis 2: Analyses over 2-y follow-up using the data obtained at V1. Abbreviations: V1, Visit 1-y; V2, Visit 2-y; V3, Visit 3-y; VE, Visit entry
Austria), 17 and SAS University edition (SAS institute, Cary, NC, USA).
For all statistical analyses, P < .05 was considered significant.
| RESULTS

| Study protocol
A flow chart is shown in Figure S1 . Once a year, all subjects visited Hokkaido University and underwent serial clinical evaluations after confirming that their asthmatic symptoms were unchanged during the past 2 weeks. During the 3-year follow-up period, 10 subjects were lost to follow-up due to withdrawal of consent, 5 subjects were excluded due to unavailability of exacerbation data, 2 subjects were excluded due to poor adherence to their medications, and 5 subjects were excluded due to unavailability of their adherence status. Additionally, 3 subjects missed Visit 1-year (V1) to Hokkaido University and were also excluded. The subjects who missed Visits 2-year (V2) and 3-year (V3), but continued to record in their asthma diaries, as well as those who visited the chief doctors in the hospital/clinic, were included in the final analysis. Ultimately, a total of 105 subjects were analysed in the current study. Table 1 reports the demographics of the subjects who were analysed in this study. At the time of enrolment, the mean age was 58.5 AE 12.1 years (range, 29-83 years) and the mean duration of asthma was 19.7 AE 14.6 years (range, 1-61 years); 42.9% of the patients were male (n = 45) and 61.9% were atopic (n = 65). Eleven (10.5%) subjects were current smokers, and 56 (53.3%) were exsmokers. Thirty-nine (37.1%) subjects used daily OCS.
| Subject demographics
| Number of exacerbations over the 3-year follow-up period (Analysis 1: from VE to V3)
Over the 3-year study period, 64 subjects (63%) had at least 1 exacerbation. As shown in Figure S2 , The scores for GERD (F-scale) and depression (Self-rating Depression Scale, SDS) did not differ among the 3 groups. The presence of AERD tended to be higher in the CFE group (P for trend = .069).
Among the several Th2-related biomarkers, blood eosinophil count and FeNO concentration were significantly higher in the CFE group than in the other 2 groups (P for trend = .032 and 0.013, respectively; Table 2 and Figure 3 ). However, total serum IgE and serum periostin levels did not differ between the 3 groups. The presence of allergic rhinitis and nasal polyps and the sinus score, as assessed with computed tomography, were not associated with the exacerbation status ( Table 2 ). The multivariate analysis revealed that FeNO concentration was an independent factor associated with CFE (P = .013), and the blood eosinophil demonstrated a tendency (P = .063; Table 3 ). Figure S4 shows the Kaplan-Meier curve demonstrating the number of days until the first asthma exacerbation over the 3-year study period. 
| Clinical evaluation after 1 year (Analysis 2: from V1 to V3)
To confirm the results from Analysis 1 (from VE to V3), using the data at initial entry (VE), we conducted similar analyses using the data obtained at V1, over 2-year follow-up (from V1 to V3; Figure 1) . The detailed clinical characteristics of the subjects obtained at V1 are reported in Tables S5 and S6 Over the 2-year follow-up, 49 subjects were classified as CNE-2 (48.0%), and 19 as CFE-2 (18.6%). When we compared the characteristics of the 3 groups using the data obtained during V1, the FeNO and the presence of AERD were significantly different between the 3 groups (P for trend = .0027, and .021, respectively).
The blood eosinophil level did not show statistical significance (P for trend = .463; Table S6 ). The impact of FeNO concentration on exacerbation status over the 2-year follow-up remained significant after adjustment of several factors (Model 1, P = .007; Table S7 ). Of importance, the impact of FeNO remained significant even after adjustment of the exacerbation status during the first year (Model 2, P = .009; Table S7 ; P = .029; Table S8 , P = .003; Table S9 ).
| DISCUSSION
In this study, our intention was to clarify the clinical characteristics and determinants of severe exacerbations in severe asthmatic subjects enrolled in the Hokkaido Severe Asthma Cohort Study. Our 3-year follow-up of severe asthmatic subjects, which included repeated measurements of a range of clinical parameters, allowed us to confirm that asthma exacerbation was a stable phenotype. In addition,
we evaluated the clinical utility of several Th2-related biomarkers for their ability to predict future exacerbation status. Notably, multivariate analyses demonstrated that the impact of FeNO upon the prediction of future asthma exacerbations remained significant even when considering "past exacerbation status" (Table 3 ). These obser- The importance of several potential biomarkers related to Th2-driven inflammatory pathways, such as blood/sputum eosinophil levels, total serum IgE level, FeNO concentration, and serum periostin level, has been extensively investigated in the management of asthma. 4, 5, 10, 11, 13, 19, 20 In addition to their similarities, the unique contributions of these markers to the several asthma phenotypes have been previously discussed. 13, 19, 21 In this study, we demonstrated that all these biomarker parameters correlated with each other.
However, the correlations were modest (R = .3-.5), confirming the differential characteristics of these parameters. Among the biomarkers, only FeNO concentration was consistently and most significantly associated with exacerbation status over the 3-year study period. The sputum eosinophil level tended to be associated with exacerbation status, suggesting that FeNO concentration is the parameter that would most accurately reflect airway inflammation which predisposes to exacerbations. Alternatively, several reports have suggested the distinct role of FeNO concentration in determining specific asthma phenotypes. [22] [23] [24] Regardless of the mechanisms involved, our results suggest that FeNO concentration, which is a non-invasive and easily measurable marker, would be useful to predict future exacerbation risk in patients with severe asthma.
In contrast, serum periostin, which is an inducible extracellular matrix protein produced by IL-13 and also a potential biomarker of airway eosinophils, 13, 19, 20 was not associated with exacerbations in our study. Recent studies have described the potential role of this molecule in facilitating airway remodelling and the potential serum markers that could predict a decline in pulmonary function in patients with asthma of varying severity.
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T A B L E 2 Comorbidity characteristics of the subjects at study entry according to the exacerbation status groups in 3-y follow-up (Analysis 1) The current asthma guidelines emphasize 3 major goals of asthma management: (i) relief of symptoms, (ii) reduction of future risk of exacerbation, and (iii) reduction in the decline of pulmonary function. 7 Accordingly, measurement of the multiple biomarkers, including FeNO concentration, can improve the quality of asthma management, particularly in regard to reducing future risks. Due to the variable nature of pulmonary function, particularly in patients with severe asthma, we believe that a 3-year follow-up period was too short to identify the factors associated with change in pulmonary function. As such, our study is still ongoing to reach a maximum of 6 years of follow-up in order to clarify the factors associated with the long-term clinical course of asthma.
In contrast to previous reports, 4,25 the presence of several asthma comorbidities, such as chronic sinusitis, obesity, and GERD, was not associated with exacerbation status in our study. However, AERD was more frequently observed in the CFE group than the other 2 groups, which confirmed a previous retrospective study conducted in Japan. 26 Although the exact reasons are unclear, the Figure 1 ) Adjusted for age, asthma duration, sex, body mass index, atopic status, smoking status (PY ≥ 10), oral corticosteroid use, and aspirin-exacerbated respiratory disease.
ethnic differences between the study's samples, ie, lower prevalence of obesity and/or GERD, 27 could explain for these discrepancies.
This study found that baseline pulmonary function, which was previously reported to be a significant factor associated with asthma exacerbation, also did not differ among the 3 groups. This may be due to the pulmonary function tests being done without a full withhold of asthma medications, perhaps levelling the measures. However, whether pulmonary function testing is done with or without a proper withhold of asthma medications could influence its utility in informing clinicians of exacerbation risk.
Our cohort studies were designed to clarify the various effects of smoking on asthma phenotypes. To achieve this goal, we intentionally included subjects who smoke/smoked and those with the potential coexistence of chronic obstructive pulmonary disease (COPD), who would require high doses of inhaled corticosteroids (ICS) and/or OCS for asthma control. We have shown that the degree of airway inflammation, which was assessed by measuring the blood and sputum eosinophils, as well as FeNO concentration, varied widely regardless of smoking status. 13 Accordingly, our inclusion criteria of smokers with/without COPD for asthmatic subjects might have significantly affected the asthma outcomes.
In contrast to our current results, several previous reports showed that FeNO might not be useful in the prediction of future exacerbation. 4, 12 The poor adherence of patients to prescribed treatment has been put forward as the predominant reason for a high rate of asthma exacerbation. A high FeNO concentration was reported to be a marker of poor adherence to medications in patients with severe asthma. 28 In our cohort, we only focused upon severe asthmatic subjects who had been managed by respiratory physicians. Most of our subjects adhered well to medicines and we also carefully excluded subjects with poor medication adherence.
This might be one of the explanations for the discrepancy between our present study and earlier reports. In fact, over 30% of our patients were on systemic corticosteroids. High FeNO levels have been reported to be the best independent factor associated with daily systemic corticosteroids. 29 Thus, high FeNO in a well-treated, severe asthma population may indicate a more complicated immune process, in general.
This study had some limitations. First, the sample size may have been too small, despite recruitment of subjects from 29 affiliated hospitals/pulmonary clinics. However, all subjects were carefully followed, and the final follow-up rate was very high at the conclusion of the third year. Second, we did not include the frequency of emergency department (ED) visits as one of the criteria of asthma exacerbation in this study. In Japan, pulmonary physicians often prescribe oral steroids for patients to be used in case of an exacerbation.
Thus, we think that the frequency of ED visits may not necessarily indicate the actual frequency of exacerbations. Third, we did not measure airway hyperresponsiveness, which could be a significant factor associated with exacerbation. Lastly, we used the older definition of severe asthma that was developed during the ATS workshop in 2000 14 since the new definition reported in the ERS/ATS guidelines 15 had not yet been officially announced when this study was designed. Nevertheless, as mentioned in the Materials and Methods section, we were certain that all subjects who were under appropriate treatment required high doses of ICS or OCS for asthma control.
In conclusion, through long-term follow-up and repeated measurements of a range of blood biomarkers, we were able to confirm that the frequent exacerbation phenotype of severe asthma appeared to be relatively stable over the 3-year study period. In addition, measurement of FeNO could be a valuable co-predictor for the management of severe asthma when combined with "past exacerbation status."
